Novel misoprostol insert reduces labor time, need for oxytocin

Novel misoprostol insert reduces labor time, need for oxytocin
Use of a 200-microgram misoprostol vaginal insert significantly reduces the time to vaginal delivery and the need for oxytocin, in women with an unfavorable cervix, compared to those using a dinoprostone vaginal insert, according to a study published online July 8 in Obstetrics & Gynecology.

(HealthDay)—Use of a 200-microgram misoprostol vaginal insert significantly reduces the time to vaginal delivery and the need for oxytocin, in women with an unfavorable cervix, compared to those using a dinoprostone vaginal insert, according to a study published online July 8 in Obstetrics & Gynecology.

Deborah A. Wing, M.D., from the University of California at Irvine, and colleagues randomly assigned women being induced with a modified Bishop score of 4 or less to receive either a 200- vaginal insert (678 patients) or a 10-mg dinoprostone vaginal insert (680 patients).

The researchers found that women receiving the misoprostol vaginal insert had a significantly shorter median time to compared with patients receiving the dinoprostone vaginal insert (21.5 hours versus 32.8 hours). Twenty-six percent of women receiving the misoprostol vaginal insert and 27.1 percent of those with the dinoprostone vaginal insert had a cesarean delivery. The misoprostol vaginal insert was significantly associated with a reduction in time to any delivery (18.3 versus 27.3 hours), time to onset of active labor (12.1 versus 18.6 hours), and proportion of women requiring predelivery (48.1 versus 74.1 percent), compared with the dinoprostone vaginal insert. Participants experienced uterine tachysystole requiring intervention in 13.3 and 4.0 percent of cases receiving the misoprostol vaginal insert and dinoprostone vaginal insert, respectively.

"Use of a 200-microgram misoprostol vaginal inset significantly reduced times to vaginal delivery and active labor with reduced need for oxytocin compared with the dinoprostone vaginal insert," the authors write.

The authors disclosed financial ties to Ferring Pharmaceuticals, which manufactures the misoprostol vaginal insert and contributed funding to the study.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Vaginal delivery ups risk of pelvic organ prolapse

Jul 02, 2013

(Medical Xpress)—Women who give birth vaginally are at increased risk of developing pelvic organ prolapse during the year after delivery, according to a study of Chinese women by researchers at Yale School ...

Recommended for you

Prolonged, heavy bleeding during menopause is common

Apr 15, 2014

Women going through menopause most likely think of it as the time for an end to predictable monthly periods. Researchers at the University of Michigan say it's normal, however, for the majority of them to experience an increase ...

Italy IVF patient pregnant with wrong embryos

Apr 13, 2014

A woman who underwent fertility treatment at a clinic in Rome became pregnant with the twins of another couple after their embryos were mixed up, press reports said Sunday.

Abuse not tied to pain severity in chronic pelvic pain

Apr 11, 2014

(HealthDay)—A history of adolescent or adult abuse is not associated with pain severity, but is linked to pain-related disability and depression in women with chronic pelvic pain (CPP), according to a study ...

User comments